2020年10月29日 · Here, we demonstrate that ABL1/2 kinase activities and/or expression are potentiated in cell lines and patient samples following resistance, and ABL1/2 drive BRAF and …

摘要： 目的： abl2属于酪氨酸激酶受体家族成员，在多种实体肿瘤中异常表达，并能在细胞表面受体的刺激作用下，广泛参与调控细胞的增殖、粘附、迁移等多种细胞功能，从而在肿瘤的进展 …

Here, we elucidate a novel link between BRAF V600E /ERK signaling and Abl kinases. We demonstrate that BRAF V600E /ERK play a critical role in binding, phosphorylating, and …

2017年4月3日 · Here we elucidate a novel link between BRAF V600E /ERK signaling and Abl kinases. We demonstrate that BRAF V600E /ERK play a critical role in binding, …

2025年1月4日 · Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling. Epidermal Growth Factor Receptor …

Puromycin was used to maintain the stable low expression of ABL2 MGC-803 cells compared with control cells; what is more, the high expression of ABL2 BGC-823 cells was also obtained. …

2018年5月16日 · All the data showed that high expression of ABL2 suppresses apoptosis through Ras/Erk and PI3K/AKT signaling pathway in GC cell lines. Diseases associated with Abelson …

2 drive BRAF and BRAF/MEK inhibitor resistance by inducing reactivation of MEK/ERK/MYC signaling. Silencing/inhibiting ABL1/2 blocks pathway reactivation, and resensitizes resistant

Here, we demonstrate that ABL1/2 kinase activities and/or expression are potentiated in cell lines and patient samples following resistance, and ABL1/2 drive BRAF and BRAF/MEK inhibitor …

2023年2月2日 · Drugs targeting the RAF/MEK/ERK pathway, which are used for BRAF -mutant melanomas, do little to increase progression-free survival (PFS). Here, using both loss-of …